Thus, the limited data to date suggest that EIF4G2 may act as either an oncogene or a tumor suppressor, depending on the tumor context, and call for a broader and deeper investigation into whether EIF4G2 gain or loss of function is indeed associated with cancer development and/or progression. The gene discussed is EIF4G2; the disease is neoplasm.